Olaya VA, Coronel MR, Robles CJ

Idioma: Español
Referencias bibliográficas: 22
Paginas: 73-78
Archivo PDF: 48.11 Kb.

RESUMEN

La leucemia aguda mieloide (LAM) representa aproximadamente 15 a 20% de todas las leucemias en la edad pediátrica. Durante la década pasada, se incrementaron los avances sobre las bases moleculares de la LAM, lo que aumentó nuestro conocimiento de la patogénesis y biología de esta enfermedad. Estos avances, en conjunto con el uso de quimioterapia intensiva postremisión vs trasplante de médula ósea (TMO) y los avances en la terapia de soporte, han mejorado la expectativa de vida de los niños con LAM. Sin embargo, sólo 40% de los niños con diagnóstico nuevo de LAM tiene espranza de curación. El reto para la siguiente década es el desarrollo de nuevas estrategias terapéuticas para el tratamiento de pacientes pediátricos con LAM.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cárdenas Cardós R. Leucemia aguda no linfoblástica, en: Rivera Luna. Diagnóstico del niño con cáncer. Mosby 1994;pp137-42.

2. Golub TR, Weinstein HF, Gerier HE. Acute myelogenous leukemia In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia. Lipincott-Raven Press, 1997;pp463-82.

3. Mejía AJ, Fajardo GA, Bernaldez RR, Farfan CJ, Ortiz FA, Martíez GM. Incidence trends of acute leukemia among the children of México City: 1982-1991. Arch Med Res (México) 1996;27(2):223-7.

4. Rivera LR, Leal LC, Cárdenas CR, Martínez AA. Survery of 4076 children with cancer. Certain epidemiological aspects from a single institution. Bol Med Hosp Inf Mex 1996;53(12):598-604.

5. Rsky RA, Smith AB, Hournung R. Benzene and leukemias, An epidemiologic risk assessment. N Engl J Med 1987;316:1044-50.

6. Yunis JJ, Bloomfield CD, Ensrud K. All patients with nonlymphoblastic leukemia may have a cromosomal defect. N Engl J Med 1981;305:135-45.

7. Larson RA, Kondo K, Vandiman JW. Evidence for a 15-17 traslocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-35.

8. Le Brau MM, Larson RA, Bitter MA. Association of inv (16) (p13q22) with abnormal marrow eosinophilis in acute myelomonocytic leukemia. A unique cytogenetic clinico-pathologic association. N Engl J Med 1983;309:630-7.

9. Jeffrey E, Rubnitz PD, Look T. Molecular genetics of chilhood leukemias. J Pediatr Hematol Oncol 1998;20:1-11.

10. Bennet JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute leukemias. Br Med Hematol 1976;33:451

11. Bennet JM, Catovsky D, Daniel MT. Criteria for the diagnosis of acute leukemia of megakariocyte lineage (M7). Ann Intern Med 1985;103:450-63.

12. Cárdenas CR, López FA. Factores pronósticos en niños con leucemia aguda no linfoblástica. Experiencia del INP en el período 1990-1997 (tesis). 1998;pp18-24

13. Forman AJ, Krance RA, O’Donell MD. Bone marrow transplantation for acute nonlymphoblastic leukemia during complete remission. Transplantation 1987;43:6509-53.

14. Amadori S, Testi AM, Arico M. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for chilhood acute myelogenous leukemia. J Clin Oncol 1993;11:1046-54.

15. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996;3334:1438-9.

16. Woogs WG, Neufdor F, Gold J. Aggresive post remission (REM) chemotherapy is better than autologous bone marrow transplantation (BMT) and allogeneic BMT is superior to both in children with acute myeloid leukemia (AML). Proc ASCO 1996;15:1091.

17. Michel G, Leverger G, Lablanc T, et al. Allogeneic bone marrow transplantation vs agressive postremission chemotherapy in children with acute myeloid leukemia in first complete remission. A prospective study of the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996;17:191-6.

18. Zitoun RA, Mandelli F, Willemze R. Autologous and allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217-23.

19. Goelam JL, Chan JY, Pignon B. Comparison of autologous bone marrow transplantation, allogeneic bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997;90:2978-86.

20. Reiffers J, Gaspard MH, Maraninchi D. Comparation of allogeneic or autologous bone marrow trasplantation and chemotherapy in patients with acute myeloid leukemia in first remission: A prospective controlled trial. Br J Hematol 1989;72:57-63.

21. Woods WG, Nobrinsky N, Buckley J, Neudorf S, Sanders L, Miller L, Bornard D. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplasic syndrome: A Children Cancer Group Pilot Study. J Clin Oncol 1993;11:1448-57.

22. Woods WG, Neudorft S, Gold S, Sanderns J, Buckley J. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children’s Cancer Group. Blood 2001;97:56-60.